Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know
10:55am, Friday, 04'th Apr 2025
The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea
How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%
10:55am, Wednesday, 19'th Mar 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is question
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
05:51am, Friday, 14'th Mar 2025
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable.
Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock
01:20pm, Tuesday, 04'th Mar 2025
Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?
04:05am, Tuesday, 04'th Mar 2025
Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be
Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High?
10:55am, Monday, 03'rd Mar 2025
The consensus price target hints at a 73.4% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea
Big Pipeline Updates From Kiniksa Pharmaceuticals
04:14pm, Tuesday, 25'th Feb 2025
Big Pipeline Updates From Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript
10:53am, Tuesday, 25'th Feb 2025
Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2024 Earnings Call Transcript
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates
09:45am, Tuesday, 25'th Feb 2025
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.06.
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
07:30am, Tuesday, 25'th Feb 2025
– ARCALYST ® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively – – ARCALYST 2025 net product revenue expected to be $560 - $580 mill
Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
07:29am, Tuesday, 25'th Feb 2025
– Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 – – KPL-387 Phase 1 single ascending dose data support potential monthly dosing – – Ki
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
04:01pm, Thursday, 20'th Feb 2025
LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 a
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
07:30am, Monday, 13'th Jan 2025
– ARCALYST ® (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth – – ARCALYST 2025 net product revenue expected to be $560 - $580 millio
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
04:01pm, Monday, 06'th Jan 2025
LONDON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
04:01pm, Tuesday, 26'th Nov 2024
LONDON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the 7th Annual Evercore ISI
